EUVIMEDEUVIMED entdecken
Crossref

Efficacy of Mirikizumab in Comparison to Ustekinumab in Patients With Moderate-to-Severe Crohn’s Disease: Results From the Phase 3 VIVID-1 Study

V. Jairath, B. E. Sands, P. Bossuyt, F. Farraye, M. Ferrante, T. Hisamatsu, A. Kaser, J. Kierkus, D. Laharie, W. Reinisch, B. Siegmund, S. M. Bragg und 6 weitere

Zeitschrift für Gastroenterologie · 01.05.2024 · 62 (05) · e481-e482

DOI: 10.1055/s-0044-1786891 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Zeitschrift für Gastroenterologie, erschienen am 01.05.2024. Verfasst von V. Jairath und 17 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Keywords: Crohn’s Disease; Mirikizumab; VIVID 1 Study Objective: Here we compared mirikizumab (miri), a p19-directed anti-IL-23 antibody, to ustekinumab (uste), a p40 directed anti-IL-12/IL-23 inhibitor, from the Phase 3, randomised, double-blind, double-dummy, active- and PBO-controlled, treat-through (TT) study, VIVID-1 (NCT03926130).

Methods

Adult pts (N=1065) were randomised 6:3:2 to miri (N=579) 900mg intravenously (IV) every 4 weeks (Q4W) to W12, then 300mg subcutaneously (SC) Q4W to W52, uste (N=287) one ~6 mg/kg IV dose, then 90mg SC Q8W to W52 or PBO (N=199).

Results

Pts treated with miri achieved all key major secondary endpoints (p

Zitieren

APA

Jairath, V., Sands, B. E., Bossuyt, P., Farraye, F., Ferrante, M., Hisamatsu, T., Kaser, A., Kierkus, J., Laharie, D., Reinisch, W., Siegmund, B., Bragg, S. M., Hon, E., Lin, Z., Lopes, M. U., Morris, N., Protic, M., & Danese, S. (2024). Efficacy of Mirikizumab in Comparison to Ustekinumab in Patients With Moderate-to-Severe Crohn’s Disease: Results From the Phase 3 VIVID-1 Study. Zeitschrift für Gastroenterologie, 62(05), e481-e482. https://doi.org/10.1055/s-0044-1786891

Vancouver

Jairath V, Sands BE, Bossuyt P, Farraye F, Ferrante M, Hisamatsu T, et al. Efficacy of Mirikizumab in Comparison to Ustekinumab in Patients With Moderate-to-Severe Crohn’s Disease: Results From the Phase 3 VIVID-1 Study. Zeitschrift für Gastroenterologie. 2024;62(05):e481-e482. doi:10.1055/s-0044-1786891

BibTeX
@article{Jairath2024,
  author = {Jairath, V. and Sands, B. E. and Bossuyt, P. and Farraye, F. and Ferrante, M. and Hisamatsu, T. and Kaser, A. and Kierkus, J. and Laharie, D. and Reinisch, W. and Siegmund, B. and Bragg, S. M. and Hon, E. and Lin, Z. and Lopes, M. U. and Morris, N. and Protic, M. and Danese, S.},
  title = {Efficacy of Mirikizumab in Comparison to Ustekinumab in Patients With Moderate-to-Severe Crohn’s Disease: Results From the Phase 3 VIVID-1 Study},
  journal = {Zeitschrift für Gastroenterologie},
  year = {2024},
  volume = {62},
  number = {05},
  pages = {e481--e482},
  doi = {10.1055/s-0044-1786891}
}
Kostenlos starten →